Neumora shuffles leadership ahead of IND—Chutes & Ladders
Neumora shuffles leadership ahead of IND—Chutes & Ladders
Neumora Therapeutics
NMRA $1.63 USD
Neumora Therapeutics | Services: Clinical-stage biotechnology developing a broad pipeline of novel medicines for neuropsychiatric and neurodegenerative (CNS) disorders, each paired with proprietary Precision Phenotype™ for targeted development; lead programs include navacaprant (Phase 3 depression), M4 agonist, NMDA antagonist | Leadership: Paul L. Berns (Co-founder, CEO since Feb 2025; succeeded Henry Gosebruch) | Keywords: CNS, neuroscience, neuropsychiatry, depression, clinical-stage, NMDA, precision medicine, biotech